Loading patent…
AssigneeProclara Biosciences, Inc.
InventorsRajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G.E. Holgate, Timothy D. Jones
Estimating the term…
The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
1-37. (canceled)
A polypeptide comprising a variant of a starting amino acid sequence, wherein the starting amino acid sequence is selected from amino acids 1-217 of SEQ ID NO:1 or amino acids 1-217 of SEQ ID NO:2, wherein:
Dependencies are inferred from the claim text.